Provided by Tiger Trade Technology Pte. Ltd.

Vaxcyte, Inc.

65.02
-1.9450-2.90%
Post-market: 65.660.6450+0.99%19:59 EDT
Volume:3.85M
Turnover:251.02M
Market Cap:9.67B
PE:-8.50
High:67.97
Open:67.14
Low:63.79
Close:66.96
52wk High:90.75
52wk Low:39.87
Shares:148.81M
Float Shares:136.00M
Volume Ratio:0.48
T/O Rate:2.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.6496
EPS(LYR):-5.6333
ROE:-36.51%
ROA:-22.61%
PB:3.51
PE(LYR):-11.54

Loading ...

Vaxcyte VAX-31 Positioned to Validate Broad Coverage, BofA Says

MT Newswires Live
·
Sep 28

Vaxcyte, Inc. : Bofa Global Research Cuts Price Objective to $130 from $133

THOMSON REUTERS
·
Sep 28

BofA Securities Adjusts Vaxcyte Price Target to $130 From $133, Maintains Buy Rating

MT Newswires Live
·
Sep 28

Vaxcyte Price Target Maintained with a $110.00/Share by Needham

Dow Jones
·
Sep 25

Vaxcyte EVP, Chief Scientific Officer and COO Jim Wassil Disposes of Common Shares Worth $493,376.94

Reuters
·
Sep 10

Vaxcyte Files Form 3 Disclosing Chief Medical Officer Luis Jodar Stake

Reuters
·
Sep 10

Vaxcyte Names New Medical and Legal Chiefs Ahead of Key Phase 3 Data

MT Newswires Live
·
Sep 04

Vaxcyte narrows previously communicated VAX-31 guidance

TIPRANKS
·
Sep 04

Vaxcyte Releases September Investor Presentation

Reuters
·
Sep 04

Vaxcyte Names Luis Jodar as Chief Medical Officer

Reuters
·
Sep 04

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected Vax-31 Opus-1 Topline Data

THOMSON REUTERS
·
Sep 04

Press Release: Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

Dow Jones
·
Sep 04

Vaxcyte COO Jim Wassil Disposes of USD 254,221.29 in Common Shares

Reuters
·
Sep 03

Vaxcyte to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Aug 28

Vaxcyte Q2 EPS $(1.97) Beats $(2.22) Estimate

Benzinga Earnings
·
Aug 06

Vaxcyte, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Vaxcyte President, CFO Andrew Guggenhime Disposes of 10,000 Common Shares Worth $538,885

Reuters
·
Aug 06

Vaxcyte Q2 FY26 Net Loss Widens to $284.3 Million; R&D Expenses Climb to $267.9 Million

Reuters
·
Aug 06

Vaxcyte Q2 Operating Expenses USD 302.777 Million

Reuters
·
Aug 06

Vaxcyte CEO Grant Pickering Disposes of Common Shares Worth $1.02 Million

Reuters
·
Jul 29